dr. yang on resistance mechanisms from osimertinib in nsclc
Published 6 years ago • 548 plays • Length 1:33Download video MP4
Download video MP3
Similar videos
-
5:46
resistance mechanisms in egfr nsclc
-
1:31
dr. oxnard on detecting resistance mechanisms after treatment with osimertinib
-
2:14
dr. yang on osimertinib as first-line therapy for egfr-positive nsclc
-
8:31
resistance mechanisms and sequencing for egfr nsclc
-
2:20
dr. liu on resistance mechanisms in egfr-mutant lung cancer
-
1:53
resistance to osimertinib in egfr-mutated nsclc
-
3:59
osimertinib for egfr t790m resistance mutations in nsclc
-
4:32
resistance mechanisms in egfr-positive nsclc
-
0:58
dr. shum on mechanisms of resistance in oncogene-driven nsclc
-
1:43
dr. padda on overcoming resistance to osimertinib in egfr nsclc
-
1:21
dr. kris on the fda approval of dacomitinib in egfr nsclc
-
1:44
dr. oxnard on delaying second-line treatment in egfr-mutant lung cancer
-
7:51
nsclc: egfr inhibition and resistance mechanisms
-
1:53
resistance to osimertinib in egfr-mutated nsclc
-
1:40
dr. piotrowska on eligibility criteria for osimertinib in lung cancer treatment
-
2:23
dr. zhu on primary resistance to osimertinib in egfr-mutant nsclc
-
1:16
dr. goldberg on options after developing resistance to osimertinib for nsclc
-
1:41
dr. goldberg on resistance to osimertinib for nsclc
-
3:48
mechanisms of resistance to upfront egfr-targeted therapy